Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Urogen Pharma (DE:UR8)
FRANKFURT:UR8
Urogen Pharma (UR8) Stock Price & Analysis
0 Followers
UR8 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€7.10 - €21.20
Previous Close€13.8
Volume0.00
Average Volume (3M)258.00
Market Cap
€471.87M
Enterprise Value€427.45M
Total Cash (Recent Filing)$147.42M
Total Debt (Recent Filing)$99.54M
Price to Earnings (P/E)N/A
Beta0.50
Next Earnings
May 09, 2024EPS Estimate
-€0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding34,122,087
10 Day Avg. Volume0
30 Day Avg. Volume258
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-12.16
Price to Sales (P/S)26.03
Price to Cash Flow (P/CF)-7.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.53
Enterprise Value/Gross Profit7.54
Enterprise Value/Ebitda-8.19
Forecast
1Y Price Target
€32.78Price Target Upside141.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Urogen Pharma News
PremiumCompany Announcements
UroGen Pharma to Present at TD Cowen Health Care Conference
PremiumCompany Announcements
Teva Challenges UroGen Pharma’s Jelmyto Patent Rights
PremiumCompany Announcements
UroGen Pharma Shares Insights at Guggenheim Healthcare TalksOptions Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
41.56% Other Institutional Investors
58.44% Public Companies and
Individual Investors
UR8 FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest stock price was €7.10 and its highest was €21.20 in the past 12 months.
What is Urogen Pharma’s market cap?
Currently, no data Available
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is May 09, 2024 which is in 4 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on Mar 14, 2024. The company reported -€0.668 earnings per share for the quarter, missing the consensus estimate of -€0.631 by -€0.037.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is -€0.81.
How many shares outstanding does Urogen Pharma have?
Currently, no data Available
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -€0.668 in its last earnings report, missing expectations of -€0.631. Following the earnings report the stock price went down -0.633%.
Which hedge fund is a major shareholder of Urogen Pharma?
Among the largest hedge funds holding Urogen Pharma’s share is RA Capital Management. It holds Urogen Pharma’s shares valued at 46M.
---
Urogen Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€32.78 (141.06% Upside)
€32.78 (141.06% Upside)
Blogger Sentiment
Bullish
DE:UR8 Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $168.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.88%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
31.48%
Trailing 12-Months
Company Description
Urogen Pharma
UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology. Its pipeline includes upper tract urothelial carcinoma, low grade non muscle invasive bladder cancer, carcinoma in situ of the bladder, and overactive bladder. The company was founded by Asher Holzer in 2004 and is headquartered in New York, NY.
---
UR8 Stock 12 Months Forecast
Average Price Target
€32.78
▲(141.06% Upside)
Technical Analysis
Best Analysts Covering UR8
1 Year
1 Year Success Rate
12/14 ratings generated profit
1 Year Average Return
+43.31%
reiterated a buy rating 2 months ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +43.31% per trade.
---